key: cord-0861550-sop4ymr6
authors: Cismaru, Cristina; Elec, Alina Daciana; Muntean, Adriana; Moisoiu, Tudor; Lupșe, Mihaela; Antal, Oana; Elec, Florin Ioan
title: FAVIPIRAVIR IN KIDNEY TRANSPLANT RECIPIENTS WITH COVID-19: A ROMANIAN CASE SERIES
date: 2022-01-01
journal: Transplant Proc
DOI: 10.1016/j.transproceed.2021.12.011
sha: c3ab74064939596bdba3014ac041929c090501b0
doc_id: 861550
cord_uid: sop4ymr6

Background: Favipiravir (FPV) is an orally administrable antiviral drug which selectively inhibits RNA-dependent RNA polymerase and which has been repurposed for COVID-19 treatment. There is limited information on the use of FPV in kidney transplant recipients (KTx), who often have multiple comorbidities and run a higher risk for death from COVID-19. Methods: We retrospectively reviewed all KTx at our institution who got sick with COVID-19 between March 1st, 2020 and May 31st, 2021 and who received FPV (loading dose of 1800 mg x 2 on Day 1, maintenance dose 2 x 800 mg/d for 5-14 days) as part of their COVID-treatment. We analyzed demographics, clinical course, laboratory data, management and outcome. Results: Nine KTx recipients with COVID-19 received FPV, all were hospitalized. The median age was 52 (range 32–60) and women were predominant (77,7%). Eight KTx had pulmonary involvement on the chest x-ray. Upon admission one patient had mild, five had moderate, two had severe and one had critical disease. Leukopenia and increased creatinine were universally noted. Three patients had disease progression under treatment. Seven patients (77,7%) required additional oxygen and four (57,1%) needed ICU admission. Three KTx died, resulting in an overall mortality of 33,3%. Survivors did not show increased transaminases and creatinine during or after FPV treatment; leukocytes, neutrophils and platelets improved upon discharge compared with admission values. Discussion: FPV appears well tolerated by KTx with COVID-19 but its clinical benefit remains unclear. Larger analyses are needed.

During the first year of the COVID-19 pandemic there was a frustrating and protracted lack of effective antiviral treatments, so that supportive therapy and decreasing immunosuppression remained the cornerstones of COVID-19 management in transplanted patients. Repurposed drugs such as hydroxychloroquine, antiretrovirals and remdesivir have also been used with negative, conflicting or inconclusive results [1, 2] . Favipiravir (FPV) is a synthetic prodrug approved in Japan for the management of the emerging 2014 influenza pandemic, which has also been repurposed and tested in COVID-19. It inhibits the RNAdependent RNA-polymerase leading to termination of viral protein synthesis [3] . The influenza dosing regimen in Japan is a loading dose of 3200 mg on day 1, followed by a maintenance dose of 600 mg twice daily on days 2-5. Apart for its known teratogenic effect, favipiravir appears to have a good safety profile. However, hyperuricemia, diarrhoea, reduced neutrophil count, transaminitis or QTc prolongation have been reported as potential adverse effects [4] . The limited experience with FPVr for COVID-treatment suggests that this drug induces viral clearance by 7 days and contributes to clinical improvement within 14 days, especially in patients with mild-to moderate illness and that FPV may be an option for moderate COVID-19 pneumonia treatment [5] [6] [7] [8] . However, the risk of adverse events requires careful consideration.

So far, the literature on the use of FPV in kidney transplant recipients with COVID-19 is limited to one retrospective series and several case reports, totalling less than 70 patients [9] [10] [11] [12] . There is no documented benefits of FVP in this group of patients due to the limited number of studies, most of them being case reports. In addition, the results are difficult to interpret due to simultaneous administration of other medications. Thus, the efficiency and safety of FPV in transplanted patients remain unclear. We herein report our experience with nine kidney transplant recipients infected with SARS-CoV-2 treated with FPV.

We retrospectively reviewed all kidney transplant recipients who underwent transplantation at the Clinical Institute of Urology and Renal Transplantation in Cluj-Napoca, Romania, who got sick with COVID-19 between March 1 st , 2020 and May 31 st , 2021. COVID-19 was defined as a positive result for SARS-CoV-2 RNA on real-time polymerase chain reaction assay of a nasopharyngeal swab and typical COVID-19 symptoms. We identified all the patients who were treated with favipiravir at any stage of their treatment and retrieved demographic and clinical data including age, sex, comorbidities, duration of symptoms, clinical course and laboratory data.

Favipiravir (FluGuard, Alliance Healthcare, Romania) treatment was started upon admission. All patients received favipiravir with a loading dose of 2 × 1800 mg and a maintenance dose of 2 × 800 mg for 5 to 7

days. An experienced transplant nephrologist adjusted the immunosuppression regimen according to the ERA-EDTA DESCARTES expert opinion [13] . Dexamethasone, tocilizumab, antipyretics, cough suppressants, and antibiotics were given at the discretion of the medical teams attending the patients.

All patients received anticoagulant therapy with low molecular weight heparin (LMWH) during the hospital stay.

AKI was defined as an increase in serum creatinine by 0.3 mg/dl or more within 48 hours or an increase to 1.5 times or more from baseline based on the definition of Kidney Disease: Improving Global Outcomes (KDIGO). Disease severity was classified from mild to critical according to the National Institutes of Health guidelines [14] . The comorbidity assessment was performed using the age-adjusted Charlson comorbidity index (CCI) [15] . Baseline kidney graft function (estimated glomerular filtration rate) was assessed on data collected at the last check-up before COVID-19 using the CKD-EPI formula.

The study was reviewed and approved by the Institutional Review Board of the Clinical Institute of Urology and Renal Transplantation (1/2021).

Discrete data were described by their frequency expressed as a percentage. Continuous data were expressed as median and range unless otherwise stated. Given the small group size and data distribution, Wilcoxon signed rank test was used for data analysis. A p-value < 0.05 was considered significant.

Nine KTx recipients diagnosed with COVID-19 during the study period received FPV, all during the second wave of the pandemic (autumn/winter 2020). The patients in this series had a median age of 52 (range 32-60) years and were predominantly women (77,7%). All but one were deceased donor kidney recipients and had a median time since transplant of 57 (range 4-319) months. Eight patients were on tacrolimus therapy, mycophenolate mofetil and prednisolone at the time of COVID-19 diagnosis, whereas one was on monotherapy with azathioprine. Basiliximab was used for tolerance induction in eight cases. The characteristics of all nine patients are detailed in Table 1 . Table 1 here All but one KTx recipients had bilateral opacities typical for COVID-19 noted on initial chest x-ray. The pulmonary involvement ranged from 10% to over 75% of the lung parenchyma.

Laboratory data at the time of diagnosis frequently revealed leukopenia with median white blood cell count 4,16x10 3 /ml (range, 2.1-10,62), median neutrophil count 2,74 x10 3 /ml (range 1,06-9,45) and 

All patients were hospitalized. Immunosuppression regimen was modified but in one patient: antimetabolites (mycophenolate mofetil, mycophenolic acid) were stopped in all but one patient (#7) and tacrolimus was reduced in all KTx receiving the drug. In four patients with severe or critical disease, all receiving high dose dexamethasone, immunosuppression completely withdrawn.

Acute kidney injury developed in two patients, both developing critical disease and ultimately requiring renal replacement therapy.

Seven out of nine patients (77,7%) required additional oxygen and four (57,1%) were admitted to the ICU. Three of these patients ultimately died, resulting in an overall mortality of 33%. All the other patients are alive with a follow up of at least six months. A detailed account on the clinical course of each patient is presented in Table 2 . 

Organ transplant recipients are considered a risk group for unfavourable outcome regarding Coronavirus disease 2019 (COVID-19), with reported mortality frequently exceeding 20% [1, 16, 17] . This disproportionately high mortality is most likely due to the lifelong immunosuppression affecting both the cellular and humoral immunity, and the frequent comorbidities such as diabetes, overweight, cardiovascular diseases and poor renal function.

Although administered upon hospitalization, favipiravir was given relatively late in the course of the disease, most patients reporting COVID-symptoms for longer than one week before seeking medical assistance. Joshi et al, in a preliminary report on 2158 COVID-19 cases from a Japanese observational registry where favipiravir was started within three days from diagnosis, reported the rates of clinical improvement at seven days from the start of favipiravir therapy as 73.8%, 66.6%, and 40.1% for mild, moderate, and severe disease respectively, whereas at 14 days it was 87.8%, 84.5%, and 60.3%, respectively [18] . Likewise, Doi et al. found that viral clearance within six days occurred in 66.7%, whereas median time until SARS-CoV-2 clearance was 12.8 days [19] . Although incomplete, the current results mirror well these findings and suggest FPV treatment does not always result in rapid virus clearance.

Two out of the three non-survivors had already a poor graft function before their SARS-CoV-2 infection.

This has rapidly resulted in acute kidney failure requiring renal replacement therapy. It is unlikely that FPV has contributed to this worsening, as an improvement in renal function tests was universally seen in all survivors receiving a similar regimen.

The most frequent adverse effects of FPV include gastrointestinal and psychiatric symptoms, decrease of the neutrophil count, increase of liver enzymes (aspartate aminotransferase and alanine transaminase), uric acid or blood triglycerides [4, 5] . FPV seems to have been well tolerated with no biochemical abnormalities attributable during, or at the completion of the treatment.

This case series lacks a control group making it difficult to establish the efficiency of FPV compared with other treatments. Finding a proper control group, matching the age, gender, comorbidities, and above all disease severity would have been difficult or impossible. For these reasons, we did not perform direct comparisons with patients receiving other treatments such as remdesivir and standard supportive therapy. Previous analyses in similar, larger patient groups, showed an in-hospital mortality during the second COVID-wave at around 27% [20, 21] . As the overall mortality in this series was 33,3%, it does not appear that FPV obviously impacted mortality, although this statement is purely speculative, in the absence of adequate comparisons with a well-matched control group. Interestingly, the mortality in a group of Turkish KTx recipients with COVID-pneumonia similarly treated with FPV was almost identical (35,7%) [9] .

The dramatic clinical course of a newly transplanted patient, with a duration between symptom start to death of only nine days, further underscores the negative impact of immunosuppression. It is customary that more intense immunosuppression is applied in the first months after transplantation, which together with the persistent effect of the induction therapy on the cellular immunity may explain the rapid progression towards death. Two large Spanish analyses confirmed a significantly higher risk for death in newly transplanted patients (within twelve months from transplant) [1, 20] .

The present study has several other limitations besides the absence of a control group. This was a retrospective observational study reporting on a small number of patients, and selection bias might have occurred. Although two thirds of patients presented with mild and moderate disease, which is the typical disease severity when favipiravir is currently used, some patients were sicker or progressed towards more severe forms. The use of FPV in severe and critical cases was probably motivated by the limited availability of remdesivir during the second wave, although it is unlikely that other treatments including remdesivir would have significantly improved the mortality.

Secondly, time to viral clearance and viral load was not assessed uniformly during the hospitalization but only upon discharge or around the time of patient death. Whereas this could have been interesting from epidemiologic and academic standpoint, it is known that SARS-CoV-2 can be detected in the respiratory samples of over half of the patients with severe disease up to the fourth week after symptom onset, and even longer time from other sampling locals [22, 23] .

This small case series does not allow firm conclusions about the efficiency of FPV on disease progression or mortality but suggest that a brief treatment is well tolerated by KTx patients. Further studies and larger meta-analyses are mandated to explore a potential clinical benefit of FPV in this vulnerable patient group. 

Spanish Group for the Study of COVID-19 in Transplant Recipients. COVID-19 in Solid Organ Transplant Recipients in Spain Throughout 2020: Catching the Wave? Transplantation

COVID-19 after kidney transplantation: Early outcomes and renal function following antiviral treatment

Favipiravir (T-705), a novel viral RNA polymerase inhibitor

A review of the safety of favipiravir -a potential treatment in the COVID-19 pandemic? J Virus Erad

Favipiravir for the treatment of patients with COVID-19: a systematic review and meta-analysis

Efficacy and Safety of Favipiravir in Moderate COVID-19 Pneumonia Patients without Oxygen Therapy: A Randomized, Phase III Clinical Trial. Infect Dis Ther

Association of Early Favipiravir Use with Reduced COVID-19 Fatality among Hospitalized Patients. Infect Chemother

Efficacy and safety of favipiravir, an oral RNA-dependent RNA polymerase inhibitor, in mild-tomoderate COVID-19: A randomized, comparative, open-label, multicenter, phase 3 clinical trial

COVID-19 pneumonia in kidney transplant recipients: A promising treatment algorithm in the absence of a disease-specific drug

Successful deceased donor kidney transplantation to a recipient with a history of COVID-19 treatment

Severe coronavirus disease 2019 (COVID-19) pneumonia patients treated successfully with a combination of lopinavir/ritonavir plus favipiravir: Case series. Clin Case Rep

Fatal SARS-CoV-2 infection in a renal transplant recipient. CEN Case Rep

How should I manage immunosuppression in a kidney transplant patient with COVID-19? An ERA-EDTA DESCARTES expert opinion. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association -European Renal Association

COVID-19 Treatment Guidelines Panel

Charlson's weighted index of comorbidities is useful in assessing the risk of death in septic patients

Covid-19 in kidney transplant recipients: a systematic review of the case series available three months into the pandemic

Results from the ERA-EDTA Registry indicate a high mortality due to COVID-19 in dialysis patients and kidney transplant recipients across Europe

Role of favipiravir in the treatment of COVID-19

A Prospective, Randomized, Open-Label Trial of Early versus Late Favipiravir Therapy in Hospitalized Patients with COVID-19

Spanish Society of Nephrology COVID-19 Group. Predictors of severe COVID-19 in kidney transplant recipients in the different epidemic waves: Analysis of the Spanish Registry

Comparing the First and Second Wave of COVID-19 in Kidney Transplant Recipients: An East-European Perspective. European surgical research

Advance online publication

Viral load dynamics and disease severity in patients infected with SARS-CoV-2 in Zhejiang province, China

Persistence of SARS-COV-2 in body fluids: a bystander or whistle blower

The authors gratefully acknowledge all their colleagues involved in the care of COVID-19 patients.

There are no conflicts of interests to be reported.

Immunosuppression change